GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Broadstone Net Lease

Bank of Nova Scotia

BRT Apartments

Cardinal Health

Canadian Imperial Bank of Commerce

Cisco Systems

Eastman Chemical

Gap Inc

Iron Mountain

Illinois Tool Works

Coca-Cola

Leggett & Platt

Main Street Capital

Medtronic

Medical Properties Trust

National Grid

NetApp

Realty Income Corp

Orion Office REIT

Oracle

Paramount Global

Philip Morris

Invesco S&P 500 High Dividend Low Volatility ETF

In July, we (my wife and I) received a dividend income total of $2,836.82. 2023 was up 24%. 7 months down in 2024 and the S&P 500 is still up almost 13%, despite the recent sell-offs. We have a high likelihood of a rate cut in September, but too much speculation is happening beyond that date. Time is ticking on that FOMC meeting.

Dividend Income: Lanny's July 2024 Summary

GSK is a pharmaceutical company with key segments in specialty medicine, general medicine, and vaccines. Economic uncertainties arise from political forces, inflation rates and signs of a recession, making the investment scene greatly volatile. Yet, GSK's positioning as a healthcare company, strategic acquisitions, robust financials, strong portfolio in various diseases and healthy margins amidst undervaluation makes it viable investment for steady, upside returns.

GSK: Robust Financials, Strong Portfolio And Sector Rotation To Defensives Make It A Buy

GSK PLC (LSE:GSK, NYSE:GSK) has successfully refuted claims that its discontinued heartburn drug Zantac caused cancer after an Illinois jury found that the product was not responsible for plaintiff Carrie Joiner's colorectal cancer. Joiner had alleged that she developed cancer from a carcinogenic contaminant called NDMA in the blockbuster pill.

GSK wins Illinois court battle

GSK won the latest trial over claims that discontinued heartburn drug Zantac caused cancer, as a jury on Monday found that the drug was not responsible for an Illinois woman's illness, a company spokesperson said.

GSK wins latest trial over Zantac cancer claims

India's GlaxoSmithKline Pharmaceuticals reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines.

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand

The US Food and Drug Administration (FDA) has expanded the approval of GSK PLC (LSE:GSK, NYSE:GSK)'s Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This includes patients with mismatch repair proficient or microsatellite stable tumours, which account for the majority of endometrial cancer cases.

GSK cancer drug receives expanded approval from the US regulator

UK-based Pharma giant GSK plc reported its Q2 earnings earlier today. GSK plc exceeded Q2 2024 expectations with revenue up 13%, operating profit up 18%, and EPS up 17%. GSK upgraded full-year guidance with 7-9% top-line growth forecasts, >10% growth in operating profit, and >10% EPS growth.

GSK Q2 Earnings Review: Vaccine Issues Aside, A Strong Quarter

GSK's H1 2024 earnings report is strong, with healthy sales growth, solid core EPS increase, and upgraded outlook, resulting in attractive market multiples. However, the outlook still indicates that investors need to brace for a weak H2 2024, with Arexvy's sales worth watching out for after they slipped up in H1 2024. Along with the potential negative impact from further developments in Zantac trials, the expected disappointing earnings figures indicate risks to price over the coming months.

GSK: Good Earnings Report, But Risks Ahead (Rating Downgrade)

GSK plc (NYSE:GSK ) Q2 2024 Earnings Conference Call July 31, 2024 7:00 AM ET Company Participants Nick Stone - Head, IR Emma Walmsley - CEO Tony Wood - Chief Scientific Officer Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO, ViiV Healthcare Julie Brown - CFO Conference Call Participants Peter Verdult - Citi Peter Welford - Jefferies James Gordon - JPMorgan Richard Parkes - BNP Paribas Graham Parry - Bank of America Merrill Lynch Tim Anderson - Wolfe Research Mark Purcell - Morgan Stanley Emily Field - Barclays Simon Baker - Redburn Atlantic Nick Stone Hello everyone. Welcome to today's call and webcast.

GSK plc (GSK) Q2 2024 Earnings Call Transcript

Around £1.2 billion was wiped from the value of GSK PLC (LSE:GSK, NYSE:GSK) after the drug giant's Q2 vaccine sales failed to pass muster with the City. Specifically, analysts at Shore Capital said the Shingrix, its shingles jab, "missed materially", while there was also some 'harrumphing' around the performance of its RSV inoculation, Arexvy.

GSK sees £1.2bn wiped from its value as investors grumble about vaccine miss

GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.

GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance

GSK (GSK) lifted its sales and earnings projections for the year, after a strong performance by its HIV and cancer drugs drove second-quarter sales higher.

GSK Becomes Latest Pharma Firm To Lift Outlook

GSK stock fell early Wednesday on light sales of two key vaccines, Shingrix and Arexvy, though the company otherwise beat expectations.

GSK Beats Second-Quarter Views, Raises Outlook; But Shares Fall On Shingrix Miss

GSK (GSK) came out with quarterly earnings of $1.09 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.97 per share a year ago.

GSK (GSK) Tops Q2 Earnings and Revenue Estimates

GSK shares fell Wednesday as investors concerns' about lawsuits surrounding the pharmaceutical giant's discontinued heartburn drug Zantac outweighed any positive impacts from its better-than-expected second-quarter results which saw it lift its full-year outlook.

GSK's better-than-expected results overshadowed by Zantac litigation

GSK PLC (LSE:GSK, NYSE:GSK) has raised its annual earnings and sales forecasts after a strong second-quarter performance driven by cancer and HIV treatments. However, the performance singularly failed to impress the market still worried about the potential financial whack the drug giant might take from ongoing Zantac litigation as the shares opened 1.3% lower.

GSK forecast upgrade fails to impress the market

British drugmaker GSK raised its annual earnings and sales forecasts on Wednesday and posted second-quarter results that beat market expectations, boosted by its cancer and HIV portfolio.

GSK raises annual profit and sales forecast after second quarter beat

Biogen

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.

Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?

GSK PLC (LSE:GSK, NYSE:GSK) said it has reached a confidential settlement with Ronald Kimbrow resolving the case he filed in Illinois state court, which is part of the drug giant's long-running Zantac litigation. The UK pharma giant stressed it did not admit any liability in this settlement.

GSK reaches confidential settlement in Illinois

GSK PLC's (LSE:GSK, NYSE:GSK) respiratory syncytial virus vaccine, Arexvy, has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use to extend its use to adults aged 50-59 who are at increased risk of RSV. If approved, it will be the first RSV vaccine for this age group in the EU.

GSK's vaccine receives positive European Medicines Agency opinion

British drugmaker GSK on Monday said it has agreed to confidentially settle a lawsuit in Illinois alleging its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end costly litigation.

GSK settles another Illinois Zantac lawsuit

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why GSK (GSK) is a Strong Momentum Stock

The European Union health regulator on Friday recommended expanded use of GSK's respiratory syncytial virus (RSV) vaccine in adults aged between 50 and 59.

EU regulator recommends use of GSK's RSV shot in adults aged 50 to 59

We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.

GSK Stock Before Q2 Earnings: To Buy or Not to Buy?

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Earnings Expected to Grow: Should You Buy?

News for GlaxoSmithKline Stock (GSK)